Cardiovascular Diabetology
Papers 1755
1 page of 176 pages (1,755 results)
#1Samuel Seidu (Leicester General Hospital)H-Index: 10
#2Setor K. Kunutsor (UoB: University of Bristol)H-Index: 27
Last.Kamlesh Khunti (Leicester General Hospital)H-Index: 66
view all 7 authors...
The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials. Randomised controlled trials of aspirin compared with pl...
#1Guillaume Besch (UFC: University of Franche-Comté)H-Index: 5
#2Sébastien Pili-Floury (UFC: University of Franche-Comté)H-Index: 10
Last.Romain ChopardFrancois (UFC: University of Franche-Comté)H-Index: 15
view all 13 authors...
Background Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.
#1Natia Peradze (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 2
#2Olivia M. Farr (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 20
Last.Christos S. Mantzoros (Harvard University)H-Index: 106
view all 6 authors...
Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investigation in subjects without diabetes. Aim of our study was to investigate whether high dose (3 mg) short-term (5 weeks) treatment with liraglutide in obese patients with no overt type 2 diabetes affects metabolites, lipid and lipoprotein profile and components of activin–follistatin axis in ca...
#1Sebastian Reith (RWTH Aachen University)H-Index: 14
#2Andrea Milzi (RWTH Aachen University)H-Index: 2
Last.Mathias Burgmaier (RWTH Aachen University)H-Index: 11
view all 7 authors...
Coronary calcification is associated with high risk for cardiovascular events. However, its impact on plaque vulnerability is incompletely understood. In the present study we defined the intrinsic calcification angle (ICA) as the angle externally projected by a vascular calcification and analyzed its role as novel feature of coronary plaque vulnerability in patients with type 2 diabetes. Optical coherence tomography was used to determine ICA in 219 calcifications from 56 patients with stable cor...
#1Rui Shi (Sichuan University)
#2Ke Shi (Sichuan University)H-Index: 6
Last.Shan Huang (Sichuan University)
view all 8 authors...
Patients with Diabetes mellitus (DM) are susceptible to coronary artery disease (CAD). However, the impact of DM on plaque progression in the non-stented segments of stent-implanted patients has been rarely reported. This study aimed to evaluate the impact of DM on the prevalence, characteristics and severity of coronary computed tomography angiography (CCTA) verified plaque progression in stented patients. A comparison between diabetic and non-diabetic patients was performed. A total of 98 pati...
#1Aaron Y. Kluger (Baylor University)H-Index: 2
#2Kristen M. Tecson (A&M: Texas A&M University)H-Index: 4
Last.Peter A. McCulloughH-Index: 84
view all 8 authors...
To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their c...
1 CitationsSource
#1Lucia La SalaH-Index: 15
#2Simona Mrakic-Sposta (National Research Council)H-Index: 22
Last.Antonio CerielloH-Index: 76
view all 12 authors...
Background Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the progression of diabetes and its related complications. Recently, microRNAs emerged as potential biomarkers of diseases. The aim of the present study was to evaluate microRNA-21 as a potential biomarker for the risk of developing diabetes in adults with IGT and to investigate its do...
#1Huan Liu (WHU: Wuhan University)H-Index: 1
#2Yongnan Lyu (WHU: Wuhan University)H-Index: 1
Last.Yan Li (WHU: Wuhan University)H-Index: 42
view all 7 authors...
Background There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects of testosterone on CAD as reported in literature have been considered as anti-atherosclerotic. The present study aimed to examine the possible association between serum GDF-15 and testosterone in male CAD patients.
1 CitationsSource
#1Zheng Qin (Capital Medical University)H-Index: 2
#2Kuo Zhou (Capital Medical University)H-Index: 2
Last.Yujie Zhou (Capital Medical University)H-Index: 15
view all 9 authors...
Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the main components include very-low-density lipoprotein (VLDL) in the fasting state. Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to elucidate the p...
2 CitationsSource
#1Guntram Schernthaner (Medical University of Vienna)H-Index: 1
#2Avraham Karasik (Sheba Medical Center)H-Index: 18
view all 17 authors...
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently...
Top fields of study
Type 2 diabetes
Diabetes mellitus